Magdalena Adrados

Magdalena Adrados

Auto-generated profile, based on publicly available information

Magdalena Adrados

Anatomía Patológica, Hospital Universitario de La Princesa, España

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 1992 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JBJuan Berenguer
Juan Berenguer
SMSantiago Moreno
Santiago Moreno
FLFernando Laguna
Fernando Laguna
TVTeresa Vicente
Teresa Vicente
MAMagdalena Adrados
Magdalena Adrados
EBEmilio Bouza
Emilio Bouza
Tuberculosis is a frequent complication of human immunodeficiency virus (HIV) infection. We describe the clinical manifestations and outcomes of tuberculous meningitis in patients with HIV infection, and compare them with those in non—HIV-infected patients. We reviewed the records from 1985 through 1990 at two large referral hospitals in Madrid for patients who had Mycobacterium tuberculosis isolated from cerebrospinal fluid. Of 2205 patients with tuberculosis, 455 (21 percent) also had HIV infection, of whom 45 had M. tuberculosis isolated from the cerebrospinal fluid. Of the 37 HIV-infected patients with tuberculous meningitis for whom records were available, 24 (65 percent) had clinical or radiologic evidence of extrameningeal tuberculosis at the time of admission. In 18 of 26 patients (69 percent), a CT scan of the head was abnormal. In most patients, analysis of cerebrospinal fluid showed pleocytosis (median white-cell count, 0.234×109 per liter) and hypoglycorrhachia (median glucose level, 1.3 mmol per liter), but in 43 percent (15 of 35), the level of protein in cerebrospinal fluid was normal. In four patients with HIV infection, tuberculosis was only discovered after their deaths. Of the 33 patients who received antituberculous treatment, 7 died (inhospital mortality, 21 percent). Illness lasting more than 14 days before admission and a CD4+ cell count of less than 0.2×109 per liter (200 per cubic millimeter) were associated with a poor prognosis. Comparison with tuberculous meningitis in patients without HIV infection showed that the presentation, clinical manifestations, cerebrospinal fluid findings, and mortality were generally similar in the two groups. However, of the 1750 patients without HIV infection, only 2 percent (38 patients) had tuberculous meningitis, as compared with 10 percent of the HIV-infected patients (P<0.001). HIV-infected patients with tuberculosis are at increased risk for meningitis, but infection with HIV does not appear to change the clinical manifestations or the outcome of tuberculous meningitis. (N Engl J Med 1992;326:668–72.)

1 March 2019 in European Journal of Cancer
Verified
Journal Article
Closed access
JRJ. Rogado
J. Rogado
JSJ.M. Sánchez-Torres
J.M. Sánchez-Torres
NRNuria Romero-Laorden
Nuria Romero-Laorden
ABA.I. Ballesteros
A.I. Ballesteros
VPV. Pacheco-Barcia
V. Pacheco-Barcia
RCRamon Colomer
Ramon Colomer

1 July 2012 in Laboratory Investigation
Verified
Journal Article
Closed access
SMSANTIAGO MONTES-MORENO
SANTIAGO MONTES-MORENO
LOLina Odqvist
Lina Odqvist
JDJulio A Diaz-Perez
Julio A Diaz-Perez
ALAna Batlle Lopez
Ana Batlle Lopez
SVSonia Gonzalez de Villambrosía
Sonia Gonzalez de Villambrosía
Miguel PirisMiguel Piris
Miguel Piris

13 December 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MSMiguel Sampedro-Núñez
Miguel Sampedro-Núñez
ASAna Serrano-Somavilla
Ana Serrano-Somavilla
MAMagdalena Adrados
Magdalena Adrados
JCJosé M. Cameselle-Teijeiro
José M. Cameselle-Teijeiro
CBConcepción Blanco-Carrera
Concepción Blanco-Carrera
Mónica Marazuela AzpirozMónica Marazuela Azpiroz
Mónica Marazuela Azpiroz
The immune checkpoint based therapy targeting the programmed death-1 (PD-1) receptor and its PD-L1 ligand has recently been approved for the therapy of different malignant conditions, but not yet for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). In this context, we evaluated the expression of PD-1 and PD-L1 in GEP-NETs and its potential correlations with clinical outcomes. Expression of PD-1/PD-L1 was analyzed by immunohistochemistry in 116 GEP-NETs and 48 samples of peritumoral tissue. In addition, the expression of these molecules was assessed by flow cytometry in peripheral blood mononuclear cells (PBMC) from patients with GEP-NETs (n = 32) and healthy controls (n = 32) and in intratumoral mononuclear cells (TMCs) (n = 3). Expression of PD-L1 and PD-1 was detected by immunohistochemistry in 6% and 1% of tumor tissue samples, respectively, and in 8% of peritumoral tissue samples, for both markers. We also observed that PD-1 expression by TMCs was associated with metastatic disease at diagnosis, and the levels of circulating PD-1+ PBMCs were associated with progressive disease upon follow-ups. In addition, circulating PD-1+ PBMCs were significantly correlated with PD-L1 expression by tumor cells. Our data suggest that PD-1/PD-L1 is expressed in 1 to 8% of GEP-NETs, and that this feature is significantly associated with disease evolution (p < 0.01).

1 December 1997 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
FLF. Laguna
F. Laguna
MAM. Adrados
M. Adrados
JAJ. Alvar
J. Alvar
VSVicente Soriano
Vicente Soriano
MVM. E. Valencia
M. E. Valencia
JGJ. M. González-Lahoz
J. M. González-Lahoz

11 December 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
MSMiguel Sampedro-Núñez
Miguel Sampedro-Núñez
Raul LuqueRaul Luque
Raul Luque
ARAna M. Ramos-Levi
Ana M. Ramos-Levi
Manuel D. GaheteManuel D. Gahete
Manuel D. Gahete
ASAna Serrano-Somavilla
Ana Serrano-Somavilla
Justo CastañoJusto Castaño
Justo Castaño
Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors